Therapeutic Enhancement of IL-2 Through Molecular Design

Author(s): Delanie J. Cassell, Shurjeel Choudhri, Rachel Humphrey, Robert E. Martell, Theresa Reynolds, Armen B. Shanafelt

Journal Name: Current Pharmaceutical Design

Volume 8 , Issue 24 , 2002

Become EABM
Become Reviewer
Call for Editor


A recombinant human IL-2 analog (rIL-2, Proleukin) is currently being evaluated for clinical benefit in HIV infected patients. It is approved for therapy of patients with metastatic melanoma and renal cell carcinoma. Treatment of cancer patients with rIL-2 results in durable responses but is associated with life-threatening toxicity, which limits its use to patients in relatively good health. Antitumor efficacy associated with rIL-2 therapy are hypothesized to be mediated by distinct types of cells that express structurally different forms of the IL-2 receptor. This hypothesis suggests that it might be possible to engineer an IL-2 variant addressing the risks associated with the therapeutic use of IL-2. In this article, we review the clinical experience with IL-2 and its analogs, the evidence that different IL-2 receptors may dissociate efficacy and toxicity, and describe the generation of a novel IL-2 variant with the potential for a superior therapeutic index.

Keywords: il-2, interleukin2, molecular design, recombinant interleukin, hiv infection

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2002
Page: [2171 - 2183]
Pages: 13
DOI: 10.2174/1381612023393260
Price: $65

Article Metrics

PDF: 24